Science  ·  2015  ·  Impact 4

ABSTRACT
We are still at an early stage of assessing oxytocin-based therapy for autism spectrum disorders The U.S. Centers for Disease Control and Prevention estimates the prevalence of autism spectrum disorders (ASDs) to be 1 in 68 children in the United States, yet no drugs to treat the debilitating social deficits of ASD are available. Oxytocin, a natural brain peptide produced in the hypothalamus, has received considerable attention as a potential treatment for social deficits in ASD. Acute intranasal oxytocin temporarily enhances social cognition, empathy, and reciprocity in individuals with ASD (1). However, recent clinical trials have yielded mixed results, leaving the field questioning whether oxytocin can live up to the hype.

 Paraphrase     Questionfy     Wikify     Simplify     Summarize


impact factor4
year_of_publication2015
sourceScience

AI Reader
upload a document and start your AI-powered reading
AI Writer
you focus on what matters the most, we handle the rest
Daily Digest
get customized highlights of the latest research & news